SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Trump Says Anthropic No Longer Seen as National Security Threat 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
BHP Shares Fall as Jansen Potash Project Costs Surge 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Dublin, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/2hqvvj/malignant) has announced the addition of the "Malignant Melanoma Pricing and Reimbursement" report to their offering.
With several new high cost melanoma drugs available, payer decisions on whether patients can access those drugs and under what conditions are becoming more important than ever. This report covers both analysis of past payer decisions and forward looking views based on payer interviews.
Key findings
- Prices of melanoma therapies and oncology drugs on the whole have become subject to closer scrutiny due to their high costs
- US payers have few tools for the utilization management of melanoma medicines due to limited treatment options
- Yervoy, Zelboraf, and Tafinlar fared well in health technology assessments in France and Germany, but have had limited uptake in more cost conservative markets due to their high costs
Key Topics Covered:
1. Executive Summary
2. Market Context
- Market entry of new drugs will dramatically increase the budget impact of melanoma treatments
- Marketed malignant melanoma products in the US, Japan, and five major EU markets
- Pipeline malignant melanoma treatments in late-stage development
- Price assumptions
- Bibliography
3. US
- Pricing
- Reimbursement
- Bibliography
4. Japan
- Successful pricing outcomes hinge on receipt of a pricing premium
- Nivolumab was awarded a 60% innovation margin
- Bibliography
5. Five Major EU Markets
- Pricing
- Reimbursement and health technology assessment
- Bibliography
For more information visit http://www.researchandmarkets.com/research/2hqvvj/malignant
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology
